← Oncology Approval Tracker

FDA DECISION ·

Keytruda + chemotherapy

pembrolizumab with chemotherapy, with or without bevacizumab · Merck

FDA approvalNew or expanded indicationCervical cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with persistent, recurrent or metastatic cervical cancer and PD-L1 combined positive score of at least 1 by an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

The regimen adds PD-1 inhibition to chemotherapy, with a bevacizumab option, in a defined cervical cancer population.

What research teams should watch

Capture PD-L1 CPS and the selected backbone and document when bevacizumab is included.

PRIMARY RECORDS

Sources